BIOCON Biocon Q2 FY26 results (Jul–Sep 2025) and concall
Biocon delivered a strong Q2 FY26, with group operating revenue growing 20% year-on-year to ₹4,296 crores, primarily driven by robust biosimilars and generics segments. Core EBITDA rose 23% to ₹1,218 crores with a 28% margin, while profit before tax surged 153%. The company also made significant progress in debt reduction and biosimilar portfolio expansion, including U.S. FDA approval for bDenosumab and successful launches of five biosimilar products, despite modest growth in the CRDMO segment.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 19.7%, net profit up 392.6% against the same quarter last year.
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|
| Revenue | 3,590 | 3,821 | 4,417 | 3,942 | 4,296 +20% |
| EBITDA | 685 | 752 | 1,078 | 766 | 835 +22% |
| Net profit | 27 | 81 | 459 | 89 | 133 +393% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
